Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
GSK core OTCs outpace market growth; Sanofi consumer business surges in emerging markets; broad drivers fuel GNC growth; USANA builds bonds in China; bullish Mead Johnson raises outlook; more Sales & Earnings In Brief.
You may also be interested in...
Sales & Earnings In Brief
Sanofi’s Allegra down from year-ago launch as stocking declines; competitive China landscape weighs on Mead Johnson; GNC revenue up double digits across segments; Claritin shows life in Merck consumer unit; USANA reports return to Western growth; Nu Skin preps ageLOC weight management launch.
Sales & Earnings In Brief
Sanofi’s Allegra down from year-ago launch as stocking declines; competitive China landscape weighs on Mead Johnson; GNC revenue up double digits across segments; Claritin shows life in Merck consumer unit; USANA reports return to Western growth; Nu Skin preps ageLOC weight management launch.
Only Alli Remains After Glaxo’s OTC Transaction With Aspen
GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.